Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 47-54

  Hong, Liu Seifert ^a   Kinon, Bruce J ^a   Tennant, Christopher J ^b   Sniadecki, Jennifer ^a   Volavka, Jan ^c  

^a ELI LILLY AND COMPANY   (United States)

^b CJT Biomedical Consulting   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Antipsychotics; Hyperprolactinemia; Risperidone; Schizophrenia; Sexual dysfunction

Indexed keywords

ALCOHOL; CAFFEINE; CHLORPROMAZINE; ESTRADIOL; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; HORMONE; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; PERPHENAZINE; PIMOZIDE; PROLACTIN; RISPERIDONE; TESTOSTERONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DISEASE ASSOCIATION; EJACULATION DISORDER; ESTRADIOL BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; PREVALENCE; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SMOKING; TESTOSTERONE BLOOD LEVEL;

EID: 68149171653     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Ucok A, Incesu C, Aker T, et al. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry. 2007;22:328-333. (Pubitemid 47088198)
2. Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28:109-123. (Pubitemid 36335820)
3. Knegtering H, Boks M, Blijd C, et al. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning. J Sex Marital Ther. 2006;32:315-326. (Pubitemid 43995227)
4. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63:408-413.
5. Dossenbach M, Hodge A, Anders M, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol. 2005;8:195-201. (Pubitemid 40769260)
6. Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J. 2006;124:291-297. (Pubitemid 46210378)
7. Olfson M, Uttaro T, Carson WH, et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 2005;66:331-338. (Pubitemid 40476756)
8. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003;28(Suppl 1):69-82.
9. Rosenberg KP, Bleiberg KL, Koscis J, et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther. 2003;29:289-296. (Pubitemid 36807936)
10. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291-2314. (Pubitemid 39388605)
11. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982;170:463-467. (Pubitemid 12051650)
12. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999;156:294-298.
13. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997;26:41-54.
14. Rubin RT. Prolactin and schizophrenia. In: Meltzer HY, editor. Psychopharmacology: The Third Generation. New York: Raven Press; 1987; p. 803-808.
15. Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28(Suppl 1):53-67. (Pubitemid 36015661)
16. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28:55-68. (Pubitemid 36332229)
17. Schwartz MF, Bauman JE, Masters WH. Hyperprolactinemia and sexual disorders in men. Biol Psychiatry. 1982;17:861-876.
18. Lundberg PO, Hulter B. Sexual dysfunction in patients with hypothalamo-pituitary disorders. Exp Clin Endocrinol. 1991;98:81-88.
19. Buvat J. Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res. 2003;15:373-377. (Pubitemid 37376944)
20. Buvat J, Lemaire A, Buvat-Herbaut M, et al. Hyperprolactinemia and sexual function in men. Horm Res. 1985;22:196-203.
21. Kadioglu P, Yalin AS, Tiryakioglu O, et al. Sexual dysfunction in women with hyperprolactinemia: a pilot study report. J Urol. 2005;174:1921-1925. (Pubitemid 41546983)
22. Turna B, Apaydin E, Semerci B, et al. Women with low libido: correlation of decreased androgen levels with female sexual function index. Int J Impot Res. 2005;17:148-153. (Pubitemid 40434588)
23. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35(Suppl):S61-S66. (Pubitemid 29133026)
24. Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63(Suppl 4):12-19. (Pubitemid 34242106)
25. Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005;66:1130-1133. (Pubitemid 41442279)
26. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13:13-24. (Pubitemid 46148428)
27. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry. 1998;59(Suppl 12):17-22.
28. Altamura AC, Mauri MC, De Novellis F, et al. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine. Pharmacopsychiatry. 1989;22:246-249. (Pubitemid 20054862)
29. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54:133-139. (Pubitemid 23141515)
30. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50:723-733. (Pubitemid 23263809)
31. Krebs M, Leopold K, Hinzpeter A, et al. Current schizophrenia drugs: efficacy and side effects. Expert Opin Pharmacother. 2006;7:1005-1016. (Pubitemid 43949939)
32. Strassnig M, Brar JS, Ganguli R. Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. Schizophr Res. 2006;86:269-275. (Pubitemid 44234052)
33. Henderson DC, Borba CP, Daley TB, et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry. 2006;18:99-105.
34. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
35. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520. (Pubitemid 30191189)
36. Kapur S, Remington G, Jones C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996;153:948-950. (Pubitemid 26225470)
37. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227-235.
38. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293. (Pubitemid 29077120)
39. 2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology (Berl). 1996;124:285-287.
40. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
41. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry. 2007;164:630-637. (Pubitemid 46650195)
42. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res. 2006;85:222-231. (Pubitemid 43947541)
43. de Haan L, Lavalaye J, Linszen D, et al. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157:1019-1020. (Pubitemid 30412360)
44. Bressan RA, Costa DC, Jones HM, et al. Typical antipsychotic drugs - D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res. 2002;56:31-36.
45. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33:731-745. (Pubitemid 28128129)
46. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
47. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
48. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988,39:1172-1177. (Pubitemid 18255479)
49. Dorey G. Is smoking a cause of erectile dysfunction? A literature review. Br J Nurs. 2001;10:455-465.
50. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149:1189-1194.
51. van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics. 2003;13:169-172.
52. Montejo AL, Rico-Villademoros F. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQSALSEX) in patients with schizophrenia and other psychotic disorders. J Sex Marital Ther. 2008;34:227-239.